Evaxion A/S Q3 2023 Earnings Report

Evaxion A/S EPS Results

• Actual EPS: -$10.50
• Consensus EPS: -$9.50
• Beat/Miss: Missed by -$1.00
• One Year Ago EPS: N/A

Evaxion A/S Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Evaxion A/S Announcement Details

• Quarter: Q3 2023
• Date: 12/19/2023
• Time: Q3 2023 Earnings Release
• Conference Call Date: Tuesday, December 19, 2023
• Conference Call Time: 2:00AM ET

Evaxion A/S (NASDAQ:EVAX) is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes. This approach aims to accelerate candidate discovery, refine antigen selection and enhance the precision of vaccine design. Evaxion’s pipeline encompasses a range of oncology programs targeting solid tumors as well as prophylactic vaccine programs focused on pathogens with high unmet medical need.

Evaxion traces its origins to academic collaborations at the University of Copenhagen and has evolved into a publicly traded company listed on the NASDAQ under the ticker EVAX. The company is led by CEO Thomas Krogh Nielsen, who brings extensive experience in biotech product development and corporate strategy. Under his leadership, Evaxion has entered into research partnerships with academic institutions and industry partners to advance its pipeline through preclinical and early clinical milestones.

Serving a global market, Evaxion collaborates with research centers and biopharma organizations across Europe and North America. Its AI-driven approach is positioned to address challenges in vaccine development by reducing time-to-candidate and improving the likelihood of clinical success. As Evaxion continues to expand its technology platform and advance its pipeline, the company aims to deliver novel immunotherapies and vaccines to patients worldwide.